Michael Forer was a co-founder of Rosetta in 2001. Michael has more than 20 years’ experience in the life science sector as an entrepreneur, advisor and investor, initially at Rothschild Asset Management. As a partner at Auven Therapeutics, he led the investment in Spirogen (sold to AstraZeneca) and the spin-out of ADC Therapeutics. Michael holds a BA in economics, and a diploma in international business. Michael gained an LLB from the University of British Columbia before articling at the predecessor law firm of Norton Rose Canada.